Variations in alcohol craving and negative mood during a clinical trial of ibudilast for alcohol use disorder.

ABSTRACT:

Background

Immune medications, including ibudilast, have shown early potential in mitigating alcohol intake in preclinical models and small-scale trials for alcohol use disorder (AUD). To elucidate clinical utility and clinical mechanisms of these novel treatments, research should carefully assess medication-related changes in AUD symptomatology, including craving and negative mood, over time.

Methods

This is a secondary analysis of a 12-week randomized clinical trial of ibudilast for AUD. Participants were 102 individuals (40% female, average age 44 years) seeking treatment for AUD and randomized to ibudilast (50 mg twice-daily) or matched placebo. Clinical symptom measures of alcohol craving, depression, and anxiety were collected monthly. Growth models compared rates of c

SUBMITTER: Meredith LR 

PROVIDER: S-EPMC12638289 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature